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 Retinoic Acid Receptor-Related Orphan Receptor α  expressing T regulatory cells 
restrain allergic skin inflammation 
Sentence summary. RORα in skin Tregs restrains cutaneous allergic inflammation by 
inhibiting IL-4 expression and promoting DR3 expression 
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 ABSTRACT 
Atopic dermatitis (AD) is an allergic inflammatory skin disease characterized by 
the production of the type-2 cytokines in the skin by type-2 innate lymphoid cells (ILC2s) 
and adaptive Th2 cells, and tissue eosinophilia. Here, we show that expression of 
nuclear receptor RORalpha (RORα) in skin-resident Tregs is important for restraining 
MC903- and antigen-induced allergic skin inflammation. Specifically, targeted deletion 
of Rora in mice Tregs led in the two models to exaggerated eosinophilia driven by IL-5 
production by ILC2s and Th2 cells. RORα  expression in skin Treg cells suppressed IL-4 
expression and enhanced expression of DR3, the receptor for the skin cytokine TL1A, 
which promotes Treg function. It also inhibited TL1A-driven skin eosinophilia elicited by 
cutaneous application of MC903. We documented higher expression of RORα in skin-
resident Tregs as compared to peripheral blood circulating Tregs in humans suggesting 
that ROR alpha is an attractive therapeutic target in AD.    
 
 INTRODUCTION 
 
 Atopic dermatitis (AD) is the most common skin inflammatory disease 
affecting  ~17% of children in developed nations (1). AD lesions are characterized by 
the presence of activated Th2 cells, as well as by the expansion of ILC2s(2-4). Both Th2 
cells and ILC2s may contribute to allergic skin inflammation in AD. Cutaneous 
inflammation elicited by topical application of Calcipotriol (MC903), a low calcemic 
analog of Vitamin D, has been used as a mouse model of acute AD(5, 6). Allergic 
inflammation in this model is accompanied by expansion of ILC2s driven by epithelial 
cytokines(2, 4). More importantly, it is dependent on ILC2s; it is preserved in Rag1-/- 
mice, and is severely attenuated in Tslpr-/- mice, ILC-depleted Rag1-/- mice and ILC2 
deficient Rorasg/sg->WT bone marrow chimeras (2, 4). Cutaneous inflammation elicited 
by repeated epicutaneous application of ovalbumin or peanut extract to tape stripped 
mouse skin provides an antigen driven mouse model of acute AD (7-9). Allergic 
inflammation in this model is dependent on T cells, as it is abolished in Rag2-/- mice(9, 
10).  
  CD4+FOXP3+ T regulatory cells (Tregs) constitute a significant subset of 
immune cells residing in murine and human skin(11). Lack of Tregs in humans and mice 
results in immune dysregulation associated with allergic skin inflammation(12, 13). Treg 
numbers are unaltered in AD skin lesions(14). Thus, the role of skin resident Tregs in 
controlling allergic skin inflammation is unclear. Herein, we have dissected the 
molecular architecture of skin resident Tregs, and identified RORα as a regulator of 
genes in Tregs responsible for suppressing allergic skin inflammation.  
  
 RESULTS 
Skin Tregs exhibit an activated signature and express the transcription 
factor RORα . Specialization of tissue-resident Tregs is an important factor in 
maintaining tissue homeostasis and modulating local immune responses. To investigate 
whether skin-resident Tregs exhibit a specialized phenotype, we compared the 
phenotype of skin resident Tregs and Tregs in skin-draining lymph node (dLN). About 
45% of CD4+ T cells in ear skin expressed FOXP3, compared to ~20% of CD4+ T cells 
in dLNs (Fig.1A).  Skin Tregs localized around dermal blood vessels and inter-follicular 
areas (Fig. S1A). We compared the transcriptome of CD3+CD4+YFP+ Tregs from the 
skin and dLN of Foxp3eyfp-cre mice. Skin Tregs differed from dLN Tregs by more than 
5000 genes (at a fold change >2, and FDR< 0.05). Skin Tregs were enriched for the 
expression of genes encoding signaling receptors (Icos and Il1rl1 (ST2)), activation 
markers (Cd44 and Klrg1), effector molecules (Il10, Ctla4 and Areg), and tissue homing 
receptors (Ccr3, Ccr8 and Ccr10) (Fig. 1B). Flow cytometry demonstrated that the 
percentage of T cells that expressed ST2, ICOS, and CD44, and the expression levels 
of these markers were significantly higher in skin Tregs compared to dLN Tregs (Fig. 
1C). Rora, the gene encoding the transcriptional regulator Retinoic acid receptor-related 
orphan receptor alpha (RORα), was highly upregulated in skin Tregs (Fig. 1B). This was 
confirmed by qPCR (Fig. 1D). Importantly, RORA expression was significantly higher in 
CD4+CD25+CD127lo skin Tregs compared to circulating Tregs in humans (Fig. 1E). 
Human skin Tregs, similar to mouse skin Tregs, display an activated signature with 
increased expression of ICOS, CTLA4 and CD44(15). 
 To examine and map the fate of RORα expressing Tregs, we bred Roracre mice 
to Rosa26Yfp (R26Y) mice. In RoracreR26Y mice, YFP marks cells that are expressing, 
or previously expressed Rora. Most of skin Tregs (>90 %) in RoracreR26Y mice 
expressed YFP compared to a small fraction (~5%) of Tregs from dLNs (Fig. 1F). 
Rora+(YFP+) Tregs in the skin uniformly expressed the transcription factor HELIOS, but 
not RORγt (Fig. S1B), suggesting that RORa-expressing skin Tregs are natural Tregs. 
The percentage of ICOS+ and ST2+ Tregs, and the levels of ICOS and ST2 were 
significantly higher in Rora+(YFP+) Tregs compared to Rora-(YFP-) Tregs in dLNs (Fig. 
S1C). A negligible subset (<1%) of thymic Tregs were Rora+(YFP+) (Fig. S1D), 
suggesting that RORa+ Tregs expand and/or are induced in peripheral tissues.  
We used RoracreR26Y mice to investigate Rora expression by cell 
subpopulations in the skin. In addition to Tregs, a fraction of CD3+CD4+CD25- T cells, 
CD3+CD8+ T cells, CD3+TCRγδ+/low dermal γδ T cells, CD3+TCRγδhigh epidermal γδ T cells, 
and CD45+Lin- ILCs  in the skin were YFP+ (Rora+) (Fig. S2A). In addition, a fraction of 
CD45-EpCAM+ keratinocytes that are mostly derived from the basal layer of the 
epidermis and of CD45-EpCAM- cells, a mixture of mature keratinocytes and fibroblasts 
in the skin were YFP+ (Rora+) (Fig. S2A). The percentages of YFP+ (Rora+) cells among 
skin cell subpopulations were not significantly altered following MC903 treatment (Fig. 
S2B and C). These results show that RORα expression was not restricted to skin Tregs. 
RORα  deficiency in Tregs results in exaggerated allergic skin inflammation 
in response to topical application of MC903.	RORα is necessary for the development 
of ILC2s(16), promotes Th17 cell differentiation and antagonizes FOXP3 in vitro(17), 
suggesting a potential pro-inflammatory role. To understand how RORα regulates the 
 function and/or maintenance of skin Tregs, we generated Foxp3eyfp-creRorafl/fl mice. 
FACS analysis of skin population of cells from Foxp3egfp mice for eGFP expression 
revealed that Foxp3 expression was restricted to CD4+ T cells, and was not detected in 
any other additional skin cell population that expressed Rora in the skin, including CD8+ 
T cells, dermal and epidermal γδ T cells, ILCs and CD45- cells (Fig. S3). In addition, 
none of the Foxp3eyfp-creRorafl/fl mice had weight loss or developed the staggerer 
phenotype observed in RORα deficient Rorasg/sg mice(18). Furthermore, the numbers of 
ILCs and γδT cells in the skin were not reduced in Foxp3eyfp-creRorafl/fl mice (data not 
shown). These results suggest that Rora is deleted specifically in Tregs of Foxp3eyfp-
creRorafl/fl mice. RNA-sequencing analysis of Tregs revealed complete deletion of the 
floxed 4th exon of Rora in these mice (Fig. S4A). The numbers of YFP+ Tregs were not 
altered in the skin or dLNs of these mice (Fig. S4B), indicating that RORα is not required 
for the accumulation or maintenance of Tregs in the skin. The cytokine IL-10 is 
important for Treg function in gut and lungs (19). There was increased percentage of IL-
10+ Tregs in Foxp3eyfp-creRorafl/fl mice compared to controls (Fig. S4C).  
Topical application of MC903 to ear skin of WT mice results in increased dermal 
thickness and infiltration of CD45+ cells that include eosinophils, and CD4+ T cells(5). 
There was an increased ear thickness, accompanied with an intense cellular infiltrate, 
and significantly increased dermal thickness in Foxp3eyfp-creRorafl/fl mice compared to 
Foxp3eyfp-cre controls (Fig. 2A-C). FACS analysis revealed a three-fold increase in 
dermal infiltration by CD45+ cells in Foxp3eyfp-creRorafl/fl mice compared to Foxp3eyfp-cre 
controls (Fig. 2D). Eosinophils accounted for ~45% of CD45+ cells in the dermis of 
MC903 treated Foxp3eyfp-creRorafl/fl mice, compared to 15% in controls, yielding an eight-
 fold increase in eosinophil numbers (Fig. 2E). The percentages of basophils (ckit
-
IgE+), 
mast cells (ckit
+
IgE
+
), neutrophils (CD11b+Gr1hi), Teff cells (CD4+FOXP3-), Tregs 
(CD4+FOXP3+) and ILCs (Lineage-CD90+) infiltrating MC903 treated skin were 
comparable in Foxp3eyfp-creRorafl/fl mice and controls (data not shown). Nevertheless, the 
numbers of these cell populations were 2-3 fold higher in Foxp3eyfp-creRorafl/fl mice (Fig. 
2F,G), reflecting the ~three-fold increase in CD45+ cells.  MC903-driven allergic 
inflammation in mice of C56BL/6 background is largely dependent on TSLP(2, 4). The 
exaggerated cutaneous inflammatory response in Foxp3eyfp-creRorafl/fl mice, which are 
on C56BL/6 background, was not due to increased Tslp expression (Fig. S5A). Serum 
IgE levels, were higher in MC903 treated Foxp3eyfp-creRorafl/fl mice compared to controls 
(Fig. S5B), indicative of a heightened type-2 response  
RORα  deficiency in Tregs results in increased expression of eotaxins and 
IL-5 In MC903 Treated skin. The proportion of eosinophils in blood was comparable in 
MC903 treated Foxp3eyfp-creRorafl/fl mice and controls (Fig. S6A), suggesting that the 
exaggerated eosinophilia in MC903 treated skin of Foxp3eyfp-creRorafl/fl mice resulted 
from increased eosinophil recruitment. Eotaxins are the major eosinophil 
chemoattractants(20). There was increased expression of Ccl11 and Ccl24, which 
encode for Eotaxin 1 and Eotaxin 2, in MC903 treated skin of Foxp3eyfp-creRorafl/fl mice 
compared to controls (Fig. 3A). IL-5 plays a critical role in tissue eosinophilia by 
synergizing with eotaxins and promoting eosinophil survival in tissues(21, 22). IL-5 
levels were significantly higher in MC903 treated skin of Foxp3eyfp-creRorafl/fl mice 
compared to controls (Fig. 3B). IL-4 and IL-13 levels were comparable in the two groups 
(Fig. S6B).    
 IL-5 is predominantly produced by ILC2s and by a subset of activated Th2 
cells(23).  ILC2s exist as pre-activated resident sentinels in the dermis that rapidly 
release IL-5 and IL-13 upon stimulation(21). In contrast, Th2 cells are recruited to the 
skin at a later stage of allergic inflammation. MC903 treatment upregulated IL-33/ST2, 
CD69 expression, downregulated CD25 expression, and had negligible effect on 
KLRG1 expression on skin Lineage-CD90+ ILCs, but the changes were comparable in 
Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls. However, Il5, mRNA levels were 
significantly increased in ILCs from MC903 treated skin of Foxp3eyfp-creRorafl/fl mice 
compared to controls (Fig. 3C). There was also a two-fold increase in Il4 and Il13 mRNA 
levels in ILCs from MC903 treated skin of Foxp3eyfp-creRorafl/fl mice; however, it did not 
reach statistical significance (Fig. S6C). There was a significant increase in 
CD4+FOXP3-IL5+, but not CD4+IL-13+ or CD4+IL-4+, Teff cells in Foxp3eyfp-creRorafl/fl 
mice compared to controls (Fig. 3D). The chemokine CCL8 is upregulated in AD skin 
lesions(24), and is critical for the recruitment of CCR8 expressing IL-5+ Th2 cells to the 
skin in a mouse model of AD(24). Ccl8 expression was strongly increased in MC903 
treated skin of Foxp3eyfp-creRorafl/fl mice (Fig. 3E). In contrast, Ccl17 and Ccl22, Ccl4 and 
Ccl5 expression was comparable in Foxp3eyfp-creRorafl/fl mice and controls (Fig. S6D). 
Cxcl1, Ccl2 and Ccl7 expression demonstrated a trend towards increase in MC903 
treated skin of Foxp3eyfp-creRorafl/fl mice, which could underlie the increased influx of 
myeloid cells in these mice (Fig. 2F). 	
 
 
 
 RORα  deficiency in Tregs alters the expression of genes involved in Treg 
cell migration and function, and skews Tregs to IL-4 producing effectors.	To gain 
an understanding of how that RORα regulates the function of skin Tregs, we performed 
NGS-transcriptomic analysis on Tregs isolated from untreated and MC903 treated skin 
of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls (Table S1 and Fig. S7). We 
observed a change in ~1700 genes across the four groups examined, at a fold change 
>2, and FDR< 0.05 (Fig. 4A). Expression of the central circadian rhythm genes Nr1d1 
and Nr1d2 was decreased in skin Treg cells from Foxp3eyfp-creRorafl/fl mice compared to 
controls, consistent with the role of RORα as circadian rhythm regulator (25). Genes 
involved in signaling via TGFβ (Smad3), TNFα (Tnfa), NFκB (Irak4, Tirap), and MAPK  
(Fos and Jun) and in cell adhesion (Icam2, Itga4) were comparably expressed in Tregs 
from untreated skin of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls, and underwent 
comparable changes after MC903 treatment. Genes in the PI3K/AKT pathway were 
downregulated in RORα deficient skin Tregs. Dysregulated PI3K/AKT signaling affects 
Foxp3 and Il2ra expression in Tregs and increases their conversion to Th1 cells(26).We 
did not observe any effect on Foxp3, Il2ra or Ifng expression in our transcriptomic and 
flow cytometric analyses of skin Tregs from Foxp3eyfp-creRorafl/fl mice. Several genes 
encoding chemokines and chemokine receptors (Ccl2, Ccr3, Ccr5) were upregulated 
upon allergic skin inflammation in all mice, but to greater extent in Foxp3eyfp-creRorafl/fl 
mice. Upregulation of these genes is consistent with the increased numbers, and higher 
velocity, of Tregs in MC903 treated skin of Foxp3IRES-egfp mice (Fig. 2G, Fig. S8A, B and 
videos 1 and 2). Furthermore, Tregs in MC903 treated skin showed less directed 
movement (Fig. S8C). Expression of Ccr6 and CCR6, thought to be important for 
 migration of Tregs into neonatal skin(27), was strongly decreased in skin Tregs from 
Foxp3eyfp-creRorafl/fl mice compared to controls, both prior to, and after, MC903 treatment 
(Fig. 4A-C). However, the numbers of skin Tregs in Foxp3eyfp-creRorafl/fl mice were not 
reduced (Fig. 3G). 
Treg suppressive activity is mediated in part by the nucleotides adenosine and 
cAMP(28). Tregs from untreated and MC903 treated skin showed strongly decreased 
expression of Nt5e, which encodes the 5’ectonucletidase CD73 that metabolizes AMP 
to adenosine(28), and reduced surface expression of CD73 compared to controls (Fig. 
4B and 4D), whereas expression of Pde3b, which encodes the phosphodiesterase 3B 
that breaks down cAMP(29), was increased (Fig. 4B). Expression of Gzmb, which 
encodes Granzyme B that mediates Treg cytotoxic activity, was upregulated (Fig. 4B), 
indicating that not all genes involved in Treg function were downregulated in the 
absence of RORα. 
Expression of IL-4 in Treg cells inhibits their ability to suppress Th2 cells and 
ILC2s(30, 31). Il4 levels were elevated in skin Tregs from Foxp3eyfp-creRorafl/fl mice 
compared to controls (Fig. 4A, B). This was confirmed by q-PCR (Fig. 4E). Furthermore, 
the percentage of CD4+Foxp3+ Tregs among IL-4 expressing CD4+ cells in MC903 
treated skin was significantly higher in Foxp3eyfp-creRorafl/fl mice compared to controls 
(Fig. 4F). These results suggest that RORα expression prevents the conversion of 
Tregs into IL-4 producing effectors. The transcription factor RUNX1 inhibits Il4 
expression in Tregs(32). Runx1 expression was decreased in Tregs from Foxp3eyfp-
creRorafl/fl mice (Fig. 5B), suggesting that reduced RUNX1 activity may de-repress Il4 
expression in RORα deficient Tregs. Tregs from MC903 treated skin of Foxp3eyfp-
 creRorafl/fl mice, but not controls, expressed Ccl8 and Ccl24 transcripts (Fig. 4B), 
suggesting that these Tregs contribute to the exaggerated eosinophil dominated allergic 
skin inflammation in Foxp3eyfp-creRorafl/fl mice. 	
  RORα  expression in Tregs promotes expression of the TL1A ligand DR3 
and restrains TL1A driven allergic inflammation elicited by cutaneous application 
of MC903.  Tnfrsf25 encodes the TNF receptor family member DR3, which is expressed 
constitutively on T cells, including Tregs, and ILC2s(33, 34). Tnfrsf25 expression as 
determined by RNASeq analysis, and DR3 surface expression as determined by FACS 
analysis, were both strongly reduced in skin Tregs from Foxp3eyfp-creRorafl/fl mice 
compared to Foxp3eyfp-cre controls (Fig. 4B, 5A and 5B). In contrast, DR3 surface 
expression by skin ILC2s was comparable in Foxp3eyfp-creRorafl/fl mice and controls (Fig. 
5C). The DR3 ligand TL1A is released by endothelial cells and myeloid cell. TL1A 
synergizes with the epithelial cytokines IL-33, IL-7 and IL-25 to enhance IL-5 expression 
in human and murine ILC2s and to promote allergic inflammation(33, 35, 36).  TL1A 
also acts on Tregs to increase their proliferation and their ability to suppress allergic 
airway inflammation (34). Skin TL1A levels were not altered after MC903 treatment, and 
were comparable in Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls (Fig. 5D). Given 
this finding, we tested the hypothesis that selective downregulation of the TL1A receptor 
DR3 on Treg cells from skin of Foxp3eyfp-creRorafl/fl mice may play an important role in 
the exaggerated MC903 driven allergic inflammation observed in these mice. MC903 
mediated eosinophilia was attenuated in Tnfrsf25-/- mice (Fig. 5E), demonstrating a role 
for TL1A in MC903 driven allergic skin inflammation. Intradermal (i.d.) injection of TL1A 
into ear skin resulted in a significant increase in the percentage and numbers of 
 eosinophils, but not neutrophils, in Foxp3eyfp-creRorafl/fl mice compared to controls (Fig. 
6F). More importantly, local TL1A blockade during MC903 treatment by i.d. injection of 
neutralizing antibody to TL1A significantly reduced MC903-driven allergic skin 
inflammation in Foxp3eyfp-creRorafl/fl mice. This was evidenced by a significant decrease 
in dermal thickness, infiltration by CD45+ cells and eosinophils, and expression of Il5 
and Ccl8 compared to isotype control antibody treated mice (Fig. 6G-J). These results 
suggest that RORα expression in Tregs restrains TL1A mediated allergic skin 
inflammation and eosinophilia elicited by cutaneous application of MC903.  
RORα  deficiency in Tregs results in exaggerated skin inflammation in 
response to epicutaneous (EC) sensitization. To investigate whether RORα 
deficiency in Tregs plays a role in restraining antigen-driven T cell dependent allergic 
skin inflammation, we subjected Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls to EC 
sensitization. EC sensitization was elicited by repeated application of the antigen 
ovalbumin (OVA) to tape stripped skin as illustrated in Fig. 6A. Skin inflammation in this 
model shares many characteristics of acute AD skin lesions, including epidermal 
thickening, dermal infiltration by CD45+ cells, including eosinophils, and increased 
expression of type 2 cytokines(9, 37). Foxp3eyfp-creRorafl/fl mice EC sensitized with OVA 
exhibited significantly increased epidermal thickness and significantly increased 
infiltration by CD45
+
 cells, compared to Foxp3eyfp-cre controls EC sensitized with OVA 
(Fig. 6B-D). Furthermore, the numbers of all cell populations analyzed, including 
eosinophils, basophils, neutrophils, mast cells, CD4+Foxp3- T cells, Treg cells and ILCs 
were 2-4 fold higher in OVA sensitized skin of Foxp3eyfp-creRorafl/fl mice compared to 
Foxp3eyfp-cre controls (Fig. 6E and 6F). Il4, but not Il13 mRNA levels in OVA sensitized 
 skin were significantly higher in Foxp3eyfp-creRorafl/fl mice compared to controls (Fig. 6G).  
Il5 mRNA was not detectable in sensitized skin in either group. Nevertheless, 
intracellular FACS analysis revealed that OVA sensitization caused a small but 
significant increase in the numbers of IL5+ ILCs and IL5+ CD4+FOXP3- Teff cells in 
Foxp3eyfp-cre control mice. The numbers of IL5+ ILCs and IL5+ CD4+FOXP3- Teff cells 
were 4~5 fold higher in OVA sensitized skin of Foxp3eyfp-creRorafl/fl mice than in controls 
(Fig. 6H). OVA sensitization did not result in significant changes in IL-33R/ST2, CD69, 
CD25 or KLRG1 expression by skin ILCs in Foxp3eyfp-creRorafl/fl or Foxp3eyfp-cre controls 
(data not shown). These results suggest that RORα+ Tregs play an important role in 
constraining antigen-driven skin inflammation. 
  
 DISCUSSION  
We show that skin Tregs express high levels of the transcription factor RORα.  
Deletion of Rora in Tregs does not alter the number of skin Tregs, but results in 
exaggerated type-2 allergic skin inflammation in response to topical application of 
MC903, or EC sensitization with OVA. Thus, we have identified RORα as a regulator of 
Treg genes responsible for suppressing allergic skin inflammation.  
The vast majority of mouse skin Tregs expressed RORα and had an activated 
phenotype. In contrast, a small minority of Tregs in skin DLNs expressed RORα  and 
had an activated phenotype. It remains to be determined whether circulating RORα+  
Tregs are specifically attracted to the skin, or whether the skin environment drives 
RORα expression in Tregs. The numbers of skin Tregs is not altered in Foxp3eyfp-
creRorafl/fl mice. Furthermore, although the majority of human blood Tregs express the 
skin homing receptor CLA(38), human blood Tregs expressed five-fold less RORA 
mRNA  compared to skin Tregs. These findings argue for local acquisition of 
RORα expression by Tregs in the skin. 
We demonstrated that RORα expression in Tregs restrains allergic skin 
inflammation induced by topical application of MC903, an AD model dependent on 
ILC2s(2, 4). This was evidenced by increased ear swelling and dermal thickness in 
Foxp3eyfp-creRorafl/fl mice, with a three fold increase in the influx of inflammatory cells that 
included T cells, basophils, neutrophils and mast cells, and a selective enrichment in 
eosinophils that showed an eight fold increase over controls. Type-2 cytokines such as 
IL-4 are documented to drive eotaxin expression(21, 39). Increased eosinophilia in 
MC903 treated skin of Foxp3eyfp-creRorafl/fl mice may be explained by synergy between 
 increased skin IL-5 expression and increased skin and Tregs eotaxin expression, likely 
driven by increased expression of IL-4 and IL-13. The exaggerated skin inflammation in 
Foxp3eyfp-creRorafl/fl mice was not caused by increased cutaneous expression of TSLP, 
the epithelial cytokine essential for MC903-driven skin inflammation in mice on the 
C57BL/6 background, the background of the Foxp3eyfp-creRorafl/fl mice we used. RORα 
was essential for repressing IL-5 expression in fast-responding ILC2s, and for restricting 
the CCL8 dependent recruitment of IL-5+ Th2 effector cells to the skin, likely by 
dampening the expression of CCl8 in the skin, and particularly in skin Treg cells. RORα 
also repressed IL-13 and IL-4 expression by skin ILCs, although the effect did not reach 
statistical significance, but had no effect on IL-4 and IL-13 expression by T cells.  We 
propose that in addition to their role in restraining adaptive immunity, a central function 
of Tregs resident in barrier interfaces, such as skin, is to inhibit the rapid activation of 
innate lymphocytes. The unrestrained activation of these innate sentinels may 
contribute to acute flare-ups in allergic diseases.  
RORα regulated the expression of several genes important for Treg migration 
and function. Changes in chemokine receptor expression may underlie the increased 
motility of Tregs in Foxp3eyfp-creRorafl/fl mice. Our data suggests that decreased 
expression by RORα deficient Tregs of Tnfrsf25 encoding DR3, a gene important for 
Treg function, contributed to the enhanced skin inflammation in Foxp3eyfp-creRorafl/fl mice. 
The exaggerated skin inflammation in Foxp3eyfp-creRorafl/fl mice may be a direct effect of 
decreased TL1A activation of Tregs and/or increased availability of TL1A to activate 
ILC2s.  Definitive evidence of the role of DR3 expression on Treg cells in limiting allergic 
skin inflammation and its mechanism of action awaits the generation and study of mice 
 with selective deficiency of Tnfrsf25  in Treg cells and/or ILC2s Furthermore, our data 
indicates that RORα restrains the conversion of Tregs into IL-4 producing effector cells; 
possibly because RORα drives the expression of Runx1 which inhibits Il4 gene 
transcription. De-repression of the Th2 pro-inflammatory genes in RORα deficient skin 
Tregs likely contributes to the enhanced allergic skin response in Foxp3eyfp-creRorafl/fl 
mice.  Furthermore, IL-10 expression was increased in RORα deficient skin Tregs. The 
transcription factor AhR enhances IL-10 production in Tregs(40) whereas IL-4 
suppresses it(41). We observed increased Ahr and Il4 expression in RORα deficient 
skin Tregs. Increased expression of AHR and IL-4 may underlie the enhanced IL-10 
expression by these cells.  
In addition to its role in suppressing ILC2 dependent allergic skin inflammation 
driven by topical application of MC903, RORα expression in Tregs was important for 
suppressing T cell dependent allergic skin inflammation driven by topical application of 
the antigen OVA to tape stripped skin, a T cell dependent mouse model of AD. This was 
evidenced by increased epidermal thickness, increased dermal infiltration by CD45+ 
inflammatory cells, including eosinophils, mast cells neutrophils, T cells and ILC2s, and 
increased cutaneous expression of Il4 and increased expression of IL-5 by T cells and 
ILCs.  
We demonstrate significantly higher expression of RORA in human skin Tregs 
compared to blood Tregs, suggesting that our results may be applicable to humans. Our 
results may be particularly relevant to patients with AD, a disease in which both Th2 
cells and ILC2s play important roles in allergic skin inflammation. RORA polymorphisms 
in asthma(42) and Rora downregulation in dogs with AD (43)  further suggest  that 
 RORα may play a regulatory role in atopic diseases. Moreover, expression of Rora in 
Tregs resident in tissues such as gut(44) may endow them with the ability to dampen 
allergic inflammation in organs other than skin. 	
	
	
	 	
 MATERIALS AND METHODS 
Mice. Foxp3eyfp-cre (C57BL/6) mice, R26R (C57BL/6) mice, Rag1-/- (C57BL/6) mice, 
Rorcgfp (C57BL/6) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). 
Rorafl/fl (C57BL/6) mice were generated in the laboratory of Dr. Pierre Chambon (France) 
(45). Roracre (C57BL/6) mice were generated in the laboratory of Dr. Dennis O’ Leary 
(46). Tnfrsf25-/- mice were generated by Dr. E. Y Wang and were obtained from the 
laboratory of Dr. Richard Siegel. Foxp3Egfp reporter mice were a gift from Dr. Talal 
Chatila. All mice were kept in a pathogen-free environment. All procedures performed on 
the mice were in accordance with the Animal Care and Use Committee of the Children's 
Hospital Boston. 
Preparation of skin cell homogenates from mice and human skin. Dorsal and 
ventral ear murine skin was separated using tweezers, chopped and digested in 
complete DMEM containing Liberase TL (2.5mg/ml, Roche, Life technologies) and 
DNAse I (20ng/ml, Sigma) for 90 minutes at 37 °C, with vigorous shaking. Digested 
tissue was mechanically disrupted with a plunger, filtered, washed and suspended in 
media for flow-cytometric analysis. Human skin surgical discards of facial skin were 
obtained from the lab. of Dr. Rachael Clark (Brigham’s and Woman’s Hospital). To 
obtain cells from human skin, all the fat was removed using a scalpel and the skin was 
chopped in small pieces and digested for 2 hours at 37 °C with vigorous shaking in 
complete RPMI containing Collagenease IV (2ng/ml, Worthington pharmaceuticals), 
Hyaluronidase (2ng/ml, Sigma), and DNase I. Digested tissue was mechanically 
disrupted using a plunger, filtered, centrifuged and resuspended for cell sorting.  
Flow cytometry. All antibodies were obtained from ebiosciences and Biolegend 
 except anti-mouse-Siglec F, which was purchased from BD biosciences. Cells were pre-
incubated with FcgR-specific blocking mAb (2.4G2) and washed before staining. 
Staining with CD45 and fixable-viability dye (ebioscience) was utilized for FACS analysis 
of skin cell homogenates. 123 count beads from ebioscience were used for estimating 
cell counts. Cells were analyzed on LSR Fortessa (BD Biosciences), and the data was 
analyzed with FlowJo software (v9.7). 
Intracellular staining analysis for cytokines and transcription factors. LN 
and skin cell suspensions were incubated with media containing PdBU and Ionomycin, 
Golgi-plug and Golgi-stop for 3 hours. Staining for surface markers was performed, 
followed by fixation and permeabilization using BD-cytofix/cytoperm buffer. Cells were 
incubated with antibodies against cytokines, IL-4, IL-5 and IL-13, along with antibodies to 
FOXP3, overnight in perm-wash containing buffer (BD biosciences). This protocol was 
also utilized to stain cells with anti-FOXP3 and anti-HELIOS markers without quenching 
the emission of YFP in Roracre R26R mice. 
MC903 treatment. MC903 (Cat. no. 2700) was purchased from Tocris 
Biochemicals. The stock was reconstituted in ethanol. 2nm MC903 (in a volume of 20ml) 
was topically applied on the ears of mice every other day, for a total of four applications. 
Ethanol (vehicle) was applied on the control ear. Mice were sacrificed one day after the 
last application. 
RNA preparation and Q-PCR. Cells were sorted directly into lysis buffer of RNA 
isolation micro kit (Zymo Research) and RNA was prepared based on kit instructions. 
For analysis of transcripts in skin, skin tissue was stored in RNA later (Ambion) 
homogenized using tissue homogenizer and RNA was prepared using RNA isolation kits 
 (Zymo Research). Reverse transcription was performed with an iScript cDNA synthesis 
kit (Bio-Rad Laboratories). PCR reactions were run on an ABI Prism 7300 (Applied 
Biosystems) sequence detection system platform. Taqman primers and probes were 
obtained from Life technologies. The housekeeping gene ?2-microglobulin was used as 
a control. Relative mRNA expression was quantified using the 2−??Ct method. 
RNA-sequencing and transcriptomic analysis. CD3+CD4+Foxp3+ (YFP)+ Tregs 
from skin and dLNs were sorted on Aria into lysis buffer  (Pico-pure RNA isolation kit, 
Life technologies). RNA was prepared and post-DNAse treatment (Qiagen) and sent to 
Dana Farber Cancer Institute’s Molecular Biology core facility for library preparation and 
sequencing. Replicates with a minimum RIN score of 7 were processed. cDNA was 
synthesized Clontech SmartSeq v4 reagents from 500pg of RNA and fragmented to a 
mean size of 150bp with a Covaris M220 ultrasonicator. Illumina libraries were prepared 
from cDNA using Rubicon Genomics Thruplex DNAseq reagents according to 
manufacturer’s protocol. The finished dsDNA libraries were quantified and sequenced on 
a single Illumina NextSeq500 run with single-end 75bp reads by the Dana-Farber 
Cancer Institute Molecular Biology Core Facilities. TopHat was used to align reads to 
mouse genome (Mm9, NCBI) and HTSeq was used to estimate read counts. Read 
counts from all experiments are listed in Table S1. Highly correlated triplicate samples 
were used for comparative analysis (Fig. S6). DEseq2 was used to normalize data and 
access differential gene expression with false discovery rate (FDR) <0.05. Expression 
levels for individual genes are represented as reads per kb of transcript per 1M of reads 
(RPKM). Hear maps were generated using GENE-E software (Broad Institute). RNA-seq 
raw data can be accessed with the no. GSE99086. 
 Intravital 2-photon imaging. Foxp3Egfp (Balb/c) mice were anesthetized i.p. 
using ketamine (100mg/kg) and xylazine (10mg/kg). One of the ears was gently attached 
to an aluminum block using double-sided tape. Ear temperature was maintained at 33o C 
using a heating pad. GenTeal (Novartis) eye gel was spread over the ear to allow 
immersion of the 20X objective (0.95 numerical aperture). Images were acquired using 
an upright microscope (Prairie Technologies) coupled to a MaiTai Ti-sapphire laser 
(Spectra-Physics). To visualize vasculature, mice were intravenously injected with 
Qdot655 (Molecular Probes) diluted in PBS. Images were acquired with a laser 
wavelength of 900nm for optimal GFP excitation and second-harmonic generation. 
Epidermis and dermis were analyzed by acquisition of ~100mm optical stacks every 30-
60s for 15-60 min with 4mm spacing. Images were transformed into four-dimensional 
time-lapse movies and analyzed using Imaris software versions 7.4.2 and 8.4.1 
(Bitplane). Imaging experiments were performed in Balb/c background but similar results 
were observed using Foxp3Egfp (C57BL/6) mice. Balb/c mice were preferred to avoid 
autofluorescence from melanin. 
Histology. Tissue samples were stored in 10% formalin and sent to the histology 
core at CHB for processing and Hematoxylin and Eosin staining. Slides were analyzed 
on the 20X objective of bright field microscope (Nikon) and captured images were 
analyzed using Image J software for enumeration of dermal thickness. 
Local treatments by Intradermal injection. Recombinant TL1A (0.9µg/µl, Cat. 
No 753008, Biolegend), was injected intradermally into the ear of mice in a total volume 
of 10 ml every day for 3 days. Isotype antibody or anti human/ mouse TL1A antibody 
(R&D systems) was injected intradermally into the ears in a total volume of 10 µl every 
 other day for 3 days. Cells from ears were prepared and flow-cytometric analysis was 
performed as described earlier. 
EC sensitization. Six to eight week-old-female mice were epicutaneously 
sensitized for 2 weeks, as described previously(9). In brief, for each treatment female 
mice were anesthetized, and then their back skin was shaved and tape-stripped with a 
film dressing (TegadermTM; 3M). Epicutaneous sensitization consisted of applying a 1 
cm2 gauze containing 200 µg OVA (Sigma-Aldrich) to the skin after each tape stripping 
and securing it with a film dressing. Analyses were done at day 12. 
ELISAs. For detection of total IgE levels, mouse sera were prepared and ELISA 
was performed (88-50460-88, ebioscience) as per the manufacturer’s instructions. For 
quantification of cytokines in the tissue, mouse ears were flash frozen in liquid nitrogen. 
Tissue was chopped, lysed and homogenized in 500ml of T-Per-tissue protein extraction 
buffer (Cat. No. 78510, Thermo-scientific) in the presence of complete protease inhibitor 
and phosphatase inhibitors. Total protein was quantified using BCA protein assay kit 
(Cat. No.23227, Pierce) and levels of IL-5 were enumerated after normalizing to the total 
protein content in the tissue. IL-5 levels in ear skin were measured using Quantikine IL-5 
kit (M5000, R&D) and TL1A levels were measured using Duoset ELISA kit (DY1896-05, 
R&D). 
Statistical analysis. Statistical significance was determined by the Mann-
Whitney test or Anova analysis using Graph-Pad prism. A p value of <0.05 was 
considered statistically significant. 
	
	
	
	
 SUPPLEMENTARY MATERIALS 
 
Fig. S1. RORα expressing skin Tregs are HELIOS+ natural Tregs that express high 
levels of ST2 and ICOS. 
Fig. S2. Multiple skin-resident cell types express RORα. 
Fig. S3.  CD4+ T cells are the only cells that express eGFP in Foxp3egfp mice 
Fig. S4. Treg specific RORα deficiency does not affect Treg numbers in the skin, nor 
their ability to produce IL-10. 
Fig. S5. Skin TSLP and Serum IgE levels in Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre 
controls. 
Fig. S6. Effect of lack of RORα in Tregs on MC903 driven blood eosinophilia, and on IL-
4, IL-13 and chemokines in MC903 treated skin. 
Fig. S7. Analysis of correlation of RNAseq samples. 
Fig. S8. Increased number and motility of Tregs in MC903-treated ear skin. 
Table S1. Summary of RNA-seq experiments. 
Movies S1. Intravital 2-photon imaging of the untreated ear dermis of a Foxp3egfp animal. 
Movie S2. Intravital 2-photon imaging of the MC-903-treated ear dermis of  Foxp3egfp 
mice.  
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Figure captions 
Figure 1. Skin Tregs exhibit an activated signature and express the 
transcription factor RORα A. Representative flow cytometric analysis (left) and 
quantification (right) of FOXP3+ (CD3+CD4+YFP+) cells among CD4+ T cells in ear skin 
compared to dLNs from Foxp3eyfp cre mice, n=3 mice/group. B. Scatter plot of log2 
(RPKM+1) values of genes expressed in skin Tregs (X axis) compared to LN Tregs (Y 
axis) determined by NGS transcriptomic analysis. Genes that differ by more than two-
fold are shown in dark gray. Select genes are identified. C. Representative flow 
cytometric analysis (left) and quantification (right) of CD44, ICOS and ST2 expressing 
skin and dLNs Tregs, and the MFI of these markers, n=3 mice/group. D. Rora 
expression levels in sorted Tregs from skin and dLNs from Foxp3eyfp-cre mice, n=3 
mice/group. E. Rora expression levels in sorted Tregs (CD4+CD25+CD127lo) from blood 
and skin of healthy donors, n=2. F. Representative flow cytometric analysis (left) and 
quantification (right) of Rora+ (YFP+) expressing Tregs in skin and dLN of Roracre/cre 
Rosayfp/yfp mice, n=2 mice/group. Columns and bars represent mean and SEM.   * = p < 
0.05 ,   ** =  p <0.01   *** =  p< 0.001 
Figure 2. RORα deficiency in Tregs results in exaggerated skin 
inflammation in response to topical application of MC903.  A-G. Quantification of 
ear thickness at day 7 (A), representative H&E stained sections (B), quantification of 
dermal thickness (C), representative FACS analysis (left) and quantification of the 
percentages (middle) and numbers (right) of CD45+ cells (D) and eosinophils (E) and 
numbers of mast cells, neutrophils, basophils (F), CD4+FOXP3+ Tregs, CD4+FOXP3- 
 Teff cells and ILCs (G) in vehicle or MC903 treated ears of Foxp3eyfp-creRorafl/fl mice and 
Foxp3eyfp-cre controls. n=3-8 mice/group. Columns and bars represent mean and SEM. * 
= p < 0.05, *** =  p< 0.001. 
Figure 3. Increased expression of eotaxins and IL-5 in MC903 treated skin 
of Foxp3eyfp-creRorafl/fl mice. A-E. Relative Ccl11 and Ccl24 mRNA expression (A), IL-5 
levels (B), relative Il5 expression in sorted Lin-CD90+ ILCs (C), representative FACS 
analysis and quantitation of the percentages of IL-5+CD4+, IL-13+CD4+, and IL-4+CD4+ T 
eff cells (D) and relative Ccl8 mRNA expression in MC903 treated skin of Foxp3eyfp-
creRorafl/fl mice and Foxp3eyfp-cre controls. n=4-7 mice/group. Columns and bars represent 
mean and SEM  * = p < 0.05, *** =  p< 0.001. ns = not significant.    
Figure 4. RORα  deficiency in Tregs alters the expression of genes involved 
in Treg cell migration and function, and skews Tregs to IL-4 producing effectors. 
A. Heat map showing relative expression of genes clustered by K mean values in skin 
Tregs of Foxp3eyfp-cre and Foxp3eyfp-creRorafl/fl mice in the steady state and after MC903 
treatment, n=4-5 mice/group. B. Heat map showing the relative expression of select 
chemotaxis, function and inflammation genes in skin Tregs from Foxp3eyfp-creRorafl/fl 
mice and controls, n=4-5 mice/group. C-D. RNA Seq tracing of ccr6 and Nt5e 
expression (left), representative FACS analysis (middle) and MFIs (right) of CCR6 and 
CD73 expression in skin Tregs of Foxp3eyfp-cre and Foxp3eyfp-creRorafl/fl mice.   n=4-5 
mice/group. The numbers in the FACS panels represent the percentage of positive cells 
relative to fluorescence minus one (FMO) control E. Relative Il4 mRNA levels in Tregs 
from MC903 treated skin of Foxp3eyfp-creRorafl/fl mice and controls, n=4-5 mice/group. F. 
Representative FACS analysis of IL4 expression in CD4+ cells and of FOXP3 vs. CD90 
 expression in IL-4+CD4+ cells (left) and quantitation of the percentage of IL-
4+CD4+FOXP3+ cells among IL-4+CD4+ cells in the skin of MC903 treated Foxp3eyfp-
creRorafl/fl mice and controls.  
Figure 5. RORα  expression in Tregs promotes expression of the TL1A 
receptor DR3 and restrains TL1A driven allergic inflammation elicited by 
cutaneous application of MC903. A. RNA Seq tracing of Tnfrsf25 expression in skin 
Tregs from untreated and MC903 treated skin of Foxp3eyfp-cre and Foxp3eyfp-creRorafl/fl 
mice. B. Representative FACS analysis (left) and MFIs (right) of DR3 expression by 
skin Tregs of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls, n=3 mice/group. The 
numbers in the FACS panels represent the percentage of positive cells relative to 
fluorescence minus one (FMO) control. C. Representative FACS analysis of DR3 
expression by ILCs from the skin of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls. 
Results are representative of 3 independent experiments. The numbers in the FACS 
panels represent the percentage of positive cells relative to fluorescence minus one 
(FMO) control. D. TL1A levels in vehicle and MC903 treated ear skin of Foxp3eyfp-
creRorafl/fl mice and Foxp3eyfp-cre controls, n=4 mice/group. E. Representative FACS 
analysis (left) and quantification (right) of CD11b+SiglecF+ eosinophils in MC903 treated 
ears of Tnfrsf25-/- mice and WT controls. F. Representative FACS analysis  (left) and 
quantification (right) of CD11b+SiglecF+ eosinophils and CD11b+GR1high neutrophils in 
TL1A injected skin of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls, n=3 mice/group. 
G-J. Representative H&E stained sections (G), quantification of dermal thickness (H), 
quantification of CD45+ cells (right) and CD11b+SiglecF+ eosinophils (left) (I), and 
relative mRNA expression of Il5 (right) and Ccl8 (left) (J) in MC903 treated ears of 
 Foxp3eyfp-creRorafl/fl mice injected with anti-TL1A antibody or isotype control, n=4 
mice/group. Columns and bars represent mean and SEM. * = p < 0.05 , ** =  p <0.01 
Figure 6. RORα  deficiency in Tregs results in exaggerated skin 
inflammation in response to epicutaneous (EC) sensitization. A. Schematic of the 
experimental mouse model. B-H. Representative H&E stained sections (B), 
quantification of epidermal thickness (C), number of CD45+ cells (D), CD11b+SiglecF+ 
eosinophils (E) mast cells, neutrophils, basophils (left), CD4+FOXP3- Teff cells, 
CD4+FOXP3+ Tregs, and ILCs (right) (F), relative Il4 (right) and Il13 (left) mRNA 
expression (G) and numbers of IL-5+ CD4+ T cells and ILCs in saline and OVA 
sensitized skin of Foxp3eyfp-creRorafl/fl mice (also designated as cKO) and Foxp3eyfp-cre 
controls (also designated as WT). n=3-7 mice/group. Columns and bars represent mean 
and SEM. * = p < 0.05, *** =  p< 0.001. 
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Retinoic Acid Receptor-Related Orphan Receptor a expressing T regulatory cells 
restrain allergic skin inflammation 
Nidhi Malhotra1#*, Juan Manuel Leyva-Castillo1#*, Unmesh Jadhav2, Olga Barreiro3, 
Christy Kam1, Nicholas K. O’Neill2, Francoise Meylan6, Dennis O’Leary4, Pierre 
Chambon5, Ulrich H. von Andrian3, Richard M. Siegel6, Eddie C. Wang7, Ramesh 
Shivdasani2 and Raif S. Geha1
* 
  
1Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, 
MA, 2Department of Medical Oncology and Center for Functional Cancer Epigenetics, 
Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 
Boston, MA, 3Department of Microbiology and Immunobiology and HMS Center for 
Immune Imaging, Harvard Medical School, Boston, MA, 4Molecular Neurobiology 
Laboratories, The Salk Institute, La Jolla CA, 5Institut de Génétique et de Biologie 
Moléculaire et Cellulaire (CNRS UMR7104, INSERM U964), Illkirch 67404, France, 
6Immunoregulation section, Autoimmunity branch, National Institute of Arthritis and 
Musculoskeletal and Skin Diseases, National Institutes of Health Bethesda, MD, 
7Department of Microbial microbiology and Infectious diseases, School of Medicine, 
Cardiff University, CF, United Kingdom 
	
	
	
	
	
	
	
	
	
	
	
	
SUPPLEMENTARY MATERIALS 
 
Fig. S1. RORα expressing skin Tregs are HELIOS+ natural Tregs that express high 
levels of ST2 and ICOS. 
Fig. S2. Multiple skin-resident cell types express RORα. 
Fig. S3.  CD4+ T cells are the only cells that express eGFP in Foxp3egfp mice 
Fig. S4. Treg specific RORα deficiency does not affect Treg numbers in the skin, nor 
their ability to produce IL-10. 
Fig. S5. Skin TSLP and Serum IgE levels in Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre 
controls. 
Fig. S6. Effect of lack of RORα in Tregs on MC903 driven blood eosinophilia, and on IL-
4, IL-13 and chemokines in MC903 treated skin. 
Fig. S7. Analysis of correlation of RNAseq samples. 
Fig. S8. Increased number and motility of Tregs in MC903-treated ear skin. 
Table S1. Summary of RNA-seq experiments. 
Movies S1. Intravital 2-photon imaging of the untreated ear dermis of a Foxp3egfp animal. 
Movie S2. Intravital 2-photon imaging of the MC-903-treated ear dermis of  Foxp3egfp 
mice.  
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Figure S1. RORα expressing skin Tregs are HELIOS+ natural Tregs that 
express high levels of ST2 and ICOS. A. Skin Tregs are localized in the vicinity of 
dermal microvasculature as determined by intravital 2-photon microscopy using 
Foxp3egfp mice. Maximal projections of splitted channels from a representative frame of 
Supplementary Video 1 are shown. The second-harmonic signal (blue) was used to 
localize the hair follicles, which are outlined with white dots in the green channel. The 
green fluorescence observed within the hair follicles corresponds to hair 
autofluorescence and can be readily distinguished from GFP+ cells localized outside the 
follicles. Qdots were injected intravenously to visualize blood vessels (purple). B. 
Representative flow cytometric analysis showing expression of HELIOS and RORgt in 
Rora+ (YFP+) skin Tregs of Roracre R26R mice. CD4+FOXP3- skin Teff cells and 
CD3+CD4- T cells (predominantly dermal gd T cells) are used as biological controls for 
HELIOS and RORgt staining respectively. Similar results were obtained in two 
independent experiments. C. Representative FACS analysis  (left) and quantification 
(right) of HELIOS+, ICOS+ and ST2+ Rora+ (YFP+) Tregs and Rora- (YFP-) Tregs from 
dLNs of Roracre R26R mice, n=2 mice/group. D. Representative flow cytometric analysis 
of Rora (YFP) expression in CD3+CD4SP+CD25hi thymic Tregs. Similar results were 
obtained in two independent experiments. Columns and bars represent mean and SEM. 
* = p < 0.05. 
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Figure S2. Multiple skin-resident cell types express RORα. Representative 
flow cytometric analysis of RORα (YPF) expression by CD4+CD25- T cells, CD8+ T cells, 
TCR γδ+ T cells, ILCs and non-hematopoietic CD45-EPCAM+ and CD45-EPCAM- cells in 
vehicle (A) and MC903-treated (B) skin of Roracre/cre Rosayfp/yfp mice. C. Quantitative 
analysis of YFP+ expression in cell populations from vehicle and MC903-treated skin. 
n=3 mice per group. Black line represents basophils recovered from skin of MC903-
treated mice, use as negative controls.  
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Fig. S3.  CD4+ T  cells are the only cells that express eGFP in Foxp3egfp mice. 
Representative flow cytometric analysis of Foxp3 (eGFP) expression by CD4+ T cells, 
CD8+ T cells, TCR γδ+ T cells, ILCs and non-hematopoietic CD45-EPCAM+ and CD45-
EPCAM- cells in untreated skin of Foxp3eGFP mice. 
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Figure S4. Treg specific RORα deficiency does not affect Treg numbers in 
the skin, nor their ability to produce IL-10. A. Analysis of reads mapped to individual 
exons in Tregs of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls, data from 6 mice (2 
mice/replicate) per group. Expression of cre completely excises the floxed 4th exon in 
Foxp3eyfp-creRorafl/fl mice. B. Representative flow cytometric analysis (left) and 
quantification of the percentages of FOXP3+(YFP+) CD4+ T cells among CD4+ T cells 
(middle) and of the numbers of FOXP3+(YFP+) CD4+ T cells   in the ears and dLNs of 
Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls. C. Representative dot plot (left) and 
quantitation (right) of IL-10+ Tregs detected by intracellular flow cytometric analysis after 
PdBU and Ionomycin stimulation of skin cells from Foxp3eyfp-creRorafl/fl mice and 
Foxp3eyfp-cre controls. Columns and bars represent mean and SEM. ns = not significant 
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Figure S5.  Skin TSLP and Serum IgE levels in Foxp3eyfp-creRorafl/fl mice and 
Foxp3eyfp-cre controls. A-B. Skin Tslp mRNA levels (A) and serum IgE levels (B) in 
vehicle and MC903 treated Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre controls.   ** =  p 
<0.01. ns = not significant.    
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Figure S6. Effect of lack of RORα in Tregs on MC903 driven blood 
eosinophilia, and on IL-4, IL-13 and chemokines in MC903 treated skin. A. 
Representative FACS analysis (left) and quantitation of the percentages (right) of 
eosinophils in the blood of MC903 treated Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-cre 
controls, n=6 mice/group. B. IL-4 and IL-13 levels in MC903 treated ears of Foxp3eyfp-
creRorafl/fl mice and Foxp3eyfp-cre controls, n=4 mice/group. C. Relative Il4 and Il13 mRNA 
levels in ILCs sorted from MC903 treated ears of Foxp3eyfp-creRorafl/fl mice and Foxp3eyfp-
cre controls, n=7 mice/group. D, E. Relative mRNA expression of Ccl17, Ccl24, Ccl4, 
Ccl5 (D) Cxcl1, Ccl2 and Ccl7 (E) in MC903 treated ears of Foxp3eyfp-creRorafl/fl mice and 
Foxp3eyfp-cre controls. n=4 mice/group. Columns and bars represent mean and SEM. ns 
= not significant. 
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Figure S7
Figure S7. Analysis of correlation of RNAseq samples.   Representative plots 
showing high correlation among replicate RNA-seq samples (top) and    Pearson 
correlation coefficients for each pair among the three replicates (bottom). 
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Figure S8
Figure S8. Increased number and motility of Tregs in MC903-treated ear 
skin. A. The maximal projections of representative frames from intravital 2-photon 
experiments showing Tregs in the mouse ear before (left) and after 2 applications of 
MC903 (right) highlight a clear increase in GFP+ cell numbers after treatment (see also 
Supplementary Video 2). The second-harmonic signal (not shown) was used to localize 
the hair follicles, which are outlined with white dots and contain green autofluorescence 
from hair. Qdots were injected intravenously to visualize blood vessels (purple). B. 
Quantification of parameters related to Treg cell tracking (mean track speed and track 
straightness) in untreated vs. MC903-treated ears. Data show results of analysis of 120 
Tregs from four mice per group. Scatter plots with mean +/- SD are shown. Statistical 
significance was assessed by unpaired two-tailed Student’s t-test (* p-value < 0.05, n.s. 
not significant). 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
SUPPLEMENTARY TABLE 
 
Table showing the number of uniquely mapped reads after RNA-sequencing in all 
individual replicate. Similar numbers of reads were mapped from all samples. 
Table	S1	
Summary	of	RNA-seq	experiments	
RNA-seq		
Uniquely	 mapped	
reads	
WT-Skin-Treg	#1	 25,810,168	
WT-Skin-Treg	#2	 28,752,183	
WT-Skin-Treg	#3	 22,282,190	
Rora	cKO-Skin-Treg	#1	 27,938,479	
Rora	cKO	Skin-Treg	#2	 27,566,393	
Rora	cKO	Skin-Treg	#3	 30,802,101	
WT-Skin-MC-Treg	#1	 29,632,419	
WT-Skin-MC-Treg	#2	 28,327,346	
WT-Skin-MC-Treg	#3	 28,415,914	
Rora	cKO	Skin-MC-Treg	#1	 27,094,449	
Rora	cKO	Skin-MC-Treg	#2	 22,947,590	
Rora	cKO	Skin-MC-Treg	#3	 23,432,530	
WT-LN-Treg	#1	 26,790,037	
WT-LN-Treg	#2	 30,250,304	
WT-LN-Treg	#3	 27,402,886	
	
	
	
	
	
	
	
	
	
	
	
SUPPLEMENTARY MOVIES 
Supplementary movie 1 (related to Figure S1).  
Intravital 2-photon imaging of the untreated ear dermis of a Foxp3egfp animal. 
Foxp3egfp Balb/c mouse was injected i.v. with Qdot655 and prepared for intravital 
imaging of the dorsal side of an ear. The frames in the video sequence correspond to 
the maximal projection of a z-stack (16 sections spaced 
4mimaging of the dorsal side of an ear. The frames in the video sequence correspond to
 the maximal projection of a z-stack (16 sections spaced 4ll samples.outlined with white 
dots and contain green channel+ cells as well as autofluorescence of the hair follicles 
(clearly distinguishable based on morphology). Tregs were found closely apposed to the 
dermal microvasculature either sessile or actively migrating in the extravascular space. 
Supplementary movie 2 (related to Figure S8). 
Intravital 2-photon imaging of the MC-903-treated ear dermis of Foxp3egfp mice.  
Foxp3egfp Balb/c mouse were topically treated twice with MC903 in the left ear with an 
interval of 48h between treatments, followed by i.v. injection of Qdot655 and prepared 
for intravital imaging of the dorsal side of the treated ear. The frames in the video 
sequence correspond to the maximal projection of a z-stack (14 sections spaced 
4mimaging of the dorsal side of the treated ear. The frames in the video sequence 
correspond to the maximal projection of a z-stack (14 sections spaced 4repared for 
intravital imaging of 
tof t some extravascular areas due to enhanced paravascular permeability. The amount 
of GFP+ Tregs observed after the MC903 treatment exponentially increased compared 
to steady-state conditions.	
	
